Sandbox Yaz: Difference between revisions

Jump to navigation Jump to search
YazanDaaboul (talk | contribs)
YazanDaaboul (talk | contribs)
No edit summary
Line 1: Line 1:
==Coronary Angiography and Revascularization==
==Overview==
[[Cardiac catheterization]] is an [[endovascular procedure]] that aims to study [[cardiac function]] and [[Cardiac anatomy|anatomy]], as well as to diagnose and treat acute [[cardiovascular disease]]s and evaluate surgical candidates. Cardiac catheterization may be either diagnostic (no intervention) or therapeutic ([[percutaneous coronary intervention]] or [[PCI]]). However, it may also classified as coronary angiography (assess patency of coronary arteries), [[left heart catheterization]] (to assess [[blood flow]], [[heart anatomy|anatomy]], and pressures in [[Heart anatomy|left heart chambers]] and to evaluate the anatomy and function of the [[mitral valve|mitral]] and [[aortic valve|aortic]] valves), or [[right heart catheterization]] (to assess [[blood flow]], [[heart anatomy|anatomy]], and pressures in [[Heart anatomy|right heart chambers]], anatomy and function of the [[tricuspid valve|tricuspid]] and [[pulmonic valve|pulmonic]] valves, [[pulmonary artery]] pressure, and [[pulmonary capillary wedge pressure]]). Determining emergency/urgency for revascularization dictates how extensive and how thorough the pre-cardiac catheterization management will be. In the case of emergencies (e.g. [[myocardial infarction]]), patient transfer to the catheterization laboratory and immediate revascularization ([[door-to-balloon]]) precede all other steps in management. In contrast, stable patients require a more extensive work-up pre-catheterization to minimize the risk of adverse events that may develop during or following the procedure.
==Algorithm==
{{familytree/start}}
{{familytree | | | A01 | | | | | | | | | | | | | | | | | | | | | | | |A01=Is cardiac catheterization an emergency?}}
{{familytree | |,|-|^|-|.| | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | B01 | | B02 | | | | | | | | | | | | | | | | | | | | | |B01=<div style=" background: #FA8072; text-align: center; width:15em">{{fontcolor|#F8F8FF|'''Yes'''}}</div>|B02=No}}
{{familytree | |!| | | |!| | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | C01 | | |!| | | | | | | | | | | | | | | | | | | | | | |C01=<div style=" background: #FA8072; text-align: center; width:15em"> {{fontcolor|#F8F8FF|'''Refer to management of [[Acute coronary syndrome resident survival guide|<span style="color:white;">acute coronary syndromes</span>]]'''}}</div>}}
{{familytree | | | | | C02 | | | | | | | | | | | | | | | | | | | | | |C02=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Confirm that the patient has ANY of the following indications for cardiac catheterization'''<br><br>
'''''Left heart catheterization'''''<br>
❑ Canadian cardiovascular society (CCS) class III (i.e. symptoms with everyday living activities) or class IV angina (i.e. inability to perform any activity without angina or angina at rest) despite medical therapy, '''OR'''<br>
❑ Angina plus systolic dysfunction, '''OR'''<br>
❑ Uncertain diagnosis following non-invasive test and need to confirm diagnosis, '''OR'''<br>
❑ Systolic dysfunction with unexplained cause, '''OR'''<br>
❑ Survivor of sudden cardiac death, polymorphic VT, or sustained monomorphic VT, '''OR'''<br>
❑ Suspected spasm or non-atherosclerotic cause of ischemia, '''OR'''<br>
❑ High-risk stress test finding, defined as '''ANY''' of following <ref name="pmid22326193">{{cite journal| author=Marso SP, Teirstein PS, Kereiakes DJ, Moses J, Lasala J, Grantham JA| title=Percutaneous coronary intervention use in the United States: defining measures of appropriateness. | journal=JACC Cardiovasc Interv | year= 2012 | volume= 5 | issue= 2 | pages= 229-35 | pmid=22326193 | doi=10.1016/j.jcin.2011.12.004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22326193  }} </ref>:<br>
:❑ Resting LVEF < 35%
:❑ High-risk treadmill score (≤ 11)
:❑ Severe exercise LVEF < 35%
:❑ Stress-induced large perfusion defect
:❑ Stress-induced multiple perfusion defects
:❑ Large, fixed perfusion defect with LV dilation OR increased lung uptake
:❑ LV dilation or increased lung uptake
:❑ Stress-induced moderate perfusion defect with LV dilation or increased lung uptake<br><br>
'''''Right heart catheterization'''''<br>
❑ Patient in shock with unknown volume status<br>
❑ Cardiogenic shock<br>
❑ Diagnosis of follow-up of pulmonary artery hypertension<br>
❑ Patients with advanced cardiopulmonary diseases who require surgery<br>
:❑ Left-to-right shunt<br>
:❑ Valvular disease<br>
:❑ Pulmonary artery hypertension<br>
:❑ Congenital heart disease</div>
}}
{{familytree | | | | | |!| | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | D01 | | | | | | | | | | | | | | | | | | | | | |D01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Obtain a detailed history'''<br><br>
'''''History of Present Illness'''''<br>
❑ Age<br>
❑ Chest pain or chest discomfort<br>
❑ Onset of symptoms<br>
❑ Sensation of heaviness, tightness, pressure, or squeezing<br>
❑ Duration of each episode<br>
❑ Radiation to the left arm, jaw, neck, right arm, back or epigastrium<br>
❑ Timing of symptoms (morning vs. evening vs. wake patient at night)<br>
❑ Alleviating factors (e.g. medications or rest)<br>
❑ Exacerbating factors<br>
❑ Association of symptoms to food intake<br>
❑ Palpitations<br>
❑ Nausea or vomiting<br>
❑ Sweating<br>
❑ Dyspnea<br>
❑ Orthopnea<br>
❑ Dizziness<br>
❑ Weakness of extremities<br>
❑ Numbness of tingling of extremities<br>
❑ Lightheadedness<br>
❑ Syncope or presyncope<br>
❑ Increased frequency of symptoms<br>
❑ Worsening of symptom severity<br>
❑ Previous episodes<br>
❑ Recent infections<br>
❑ Fever<br>
❑ Weight or appetite changes<br>
❑ Stress<br>
❑ Fatigue<br><br>
'''''Possible Symptom Triggers'''''<br>
❑ Physical exertion<br>
❑ Air pollution or fine particulate matter<br>
❑ Recent infection<br>
❑ Heavy meal intake<br>
❑ Cocaine<br>
❑ Marijuana<br><br>
'''''Cardiovascular Risk Factors'''''<br>
❑ Known CAD (review available catheterizations or CABG reports)<br>
❑ Smoking history<br>
❑ Baseline blood pressure (Duration, antihypertensive therapy, compliance with medications)<br>
❑ History of diabetes mellitus (Duration, DM control, compliance, antidiabetic medications, recent HbA1c, screening for micro- and macrovascular DM complications)<br>
❑ Dyslipidemia<br>
❑ Obesity (BMI > 30 kg/m2)<br><br>
'''''Past Medical History'''''<br>
❑ Congenital heart disease<br>
❑ Left to right shunts<br>
❑ Dextrocardia<br>
❑ Situs inversus<br>
❑ History of renal disease (CrCl < 60 mL/min)? Does the patient currently have a stable renal function?<br>
❑ History of bleeding tendency<br>
❑ Known significant anemia (Hct < 30%)<br>
❑ History of heparin-induced thrombocytopenia (HIT)<br>
❑ History of pulmonary disease<br>
❑ History of major surgery in the past month<br>
❑ Anticipated major surgery in the next year<br><br>
'''''Medications'''''<br>
❑ Prescribed drug<br>
❑ Home oxygen therapy<br>
❑ Over-the-counter drugs<br>
❑ Herbs and supplements<br>
❑ Administration of ANY of the following medications within the last 48 hours prior to catheterization?<br>
:❑ Aspirin
:❑ Clopidogrel
:❑ Metformin
:❑ Phosphodiesterase inhibitors (e.g. Tadalafil, sildenafil, or similar drugs)
:❑ Warfarin. If yes, what is most recent INR?
:❑ Low molecular weight heparin (LMWH). If yes, when was last dose?
:❑ Other chronic anticoagualants (e.g. dabigatran, NOACs, fondaparinux)<br><br>
'''''Allergies'''''<br>
❑ List of allergies, including severity and manifestations (pruritus, rash, hives, stridor, or anaphylactic shock)<br>
❑ Known drug allergies
:❑ Allergy to aspirin or history of nasal polyps or aspirin desensitization
:❑ Allergy to heparin
:❑ Allergy to sedation medications
:❑ Other drug allergies
:❑ Contrast allergy
:❑ Latex allergy
:❑ Allergy to Shellfish (controversial association between shellfish allergy and contrast allergy)
:❑ Other known environmental and food allergies<br><br>
'''''Family History'''''<br>
❑ Family history of premature cardiovascular diseases<br><br>
'''''Social and Sexual History'''''<br>
❑ Healthcare proxy and available family members for patient care<br>
❑ Barrier to tolerate or adhere to dual antiplatelet therapy (DAPT) or follow-up visits<br>
❑ Pregnancy or possible pregnancy<br><br>
'''''Advanced Directives'''''<br>
❑ DNR status<br>
❑ DNI status</div>}}
{{familytree | | | | | |!| | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | E01 | | | | | | | | | | | | | | | | | | | | | |E01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Examine the patient'''<br><br>
❑ Vital signs, including BP, HR, RR, T, room air SpO2<br>
❑ Height (in meters), weight (in kilograms), and body mass index (BMI)<br>
❑ Level of consciousness, orientation, and ability to cooperate and communicate<br><br>
'''''Skin'''''<br>
❑ Xanthelesma or xanthoma (suggestive of dyslipidemia)<br>
❑ Edema (suggestive of congestive heart failure)<br>
❑ Acral and/or central cyanosis<br><br>
'''''HEENT'''''<br>
❑ Head and neck range of motion<br>
❑ Modified Mallampati score<br>
:❑ Class I: Soft palate, uvula, fauces, pillars visible
:❑ Class II: Soft palate, uvula, fauces visible
:❑ Class III: Soft palate, base of uvula present
:❑ Class IV: Only hard palate visible<br><br>
'''''Cardiothoracic'''''<br>
❑ Auscultation of heart sounds (including number of sounds, pitch, interval, murmurs, gallops, or rubs) over 4 precordial regions in sitting position (stethoscope diaphragm) and auscultation of mitral area while in left lateral decubitus position (stethoscope bell)<br>
:❑ Normal S1 and S2
:❑ S3 may be pathologic or may be a normal finding in young or pregnant
:❑ S4 may be pathologic or may be a normal finding in elderly
:❑ Murmur may be physiologic or may suggest valvulopathy or hemodynamic derangement (e.g. anemia)
:❑ Pericardial friction rub may suggest pericarditis<br>
❑ Point of maximal impulse (PMI) (normally one, non-sustained, tapping impulse per cardiac cycle located less than 2-3 cm from midclavicular line at 5th intercostal space)<br>
❑ Auscultation of anterior and posterior pulmonary regions bilaterally<br>
:❑ Crackles suggest pulmonary edema, which might be attributed to congestive heart failure
:❑ If pulmonary auscultation abnormal, egophony, tactile fremitus, and thoracic percussion may be needed<br><br>
'''''Vascular'''''<br>
❑ Pulses of both upper extremities (radial, ulnar, brachial) and lower extremities (dorsalis pedis, posterior tibial, popliteal)<br>
❑ Femoral pulses bilaterally<br>
❑ Femoral auscultation bilaterally for bruits<br>
❑ Modified Allen test bilaterally to evaluate adequacy of radial access<br>
❑ Carotid auscultation bilaterally<br>
❑ Jugular venous pressure<br><br>
'''''Neurological'''''<br>
❑ Upper/lower extremity motor strength<br>
❑ Upper/lower extremity sensory exam<br>
❑ Spasticity or rigidity<br>
❑ Deep tendon reflexes<br>
❑ Bilateral Babinski<br>
❑ CN assessment<br>
❑ Coordination and cerebellar exams (Finger to nose, Romberg, Heel to shin, alternating movement)<br>
❑ Gait</div>}}
{{familytree | | | | | |!| | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | F01 | | | | | | | | | | | | | | | | | | | | | |F01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Provide appropriate counseling before catheterization'''<br><br>
❑ Address individual concerns and questions<br><br>
'''''Hold Food Intake Before Procedure'''''<br>
❑ Keep patient NPO at least 6 hours before elective coronary angiography<br><br>
'''''Hold Certain Medications Before Procedure'''''<br>
''Warfarin''<br>
❑ Hold warfarin for at least 2 to 6 days before elective coronary angiography (to prevent bleeding)<br>
❑ Confirm INR < 1.8 (preferable INR < 1.4) within 24 hours before arterial puncture<br>
❑ Restart warfarin 12 to 24 hours following catheterization (warfarin requires 2 to 3 days for INR to become therapeutic range)<br>
❑ Consider heparin bridging 3 days before planned catheterization for high risk patients to prevent prolonged subtherapeutic INR<br>
:❑ Therapeutic dose LMWH 1 mg/kg subcutaneously twice daily for high-risk patients who are not at high risk of bleeding
:❑ Intermediate dose LMWH 40 mg subcutaneously twice daily for high-risk patients at high risk of bleeding<br><br>
''Novel Oral Anticoagulants''<br>
❑ Hold NOAC before catheterization as follow<br>
❑ Rivaroxaban: Hold rivaroxaban for 2 days in patients with low bleeding risk OR for 3 days in patients with high bleeding risk<br>
❑ Apixaban: Hold apixaban for 2 days in patients with low bleeding risk OR for 3 days in patients with high bleeding risk<br>
❑ If patient does not develop any hematoma, restart NOAC 1 day after the catheterization for patients with low bleeding risk OR 2-3 days after the catheterization for patients with high bleeding risk<br><br>
''Dabigatran''<br>
❑ Hold dabigatran based on renal function as shown below<br>
:❑ CrCl > 50 ml/min: Hold dabigatran for 1 day if low/intermediate bleeding risk or 3 days if high bleeding risk (e.g. major surgery)
:❑ CrCl between 30 and 50 ml/min: Hold dabigatran for 3 days if low/intermediate bleeding risk or 5 days if high bleeding risk (e.g. major surgery)
❑ CrCl < 30 ml/min: Hold dabigatran for 2 to 5 days if low/intermediate bleeding risk or > 5 days if high bleeding risk (e.g. major surgery)<br>
❑ If patient does not develop any hematoma, restart dabigatran 1 day after the catheterization for patients with low bleeding risk OR 2-3 days after the catheterization for patients with high bleeding risk<br><br>
''LMWH''<br>
❑ Hold LMWH for 12 hours before cardiac catheterization<br>
❑ Resume LMWH 12-24 hours following cardiac catheterization<br><br>
''Metformin''<br>
❑ Hold metformin 2 days before elective coronary angiography<br>
❑ Consider holding all other oral antidiabetic agents before elective coronary angiography and administering insulin instead<br>
❑ Consider endocrinology consult for appropriate administration of antidiabetic agents before and after catheterization
❑ Restart metformin (or other oral antidiabetic agents) 2 days post-procedure OR until creatinine is stable (to prevent lactic acidosis and contrast-induced renal failure)<br><br>
''Phosphodiesterase inhibitors''<br>
❑ Hold sildenafil/tadalafil/vardenafil for at least 2 days before elective coronary angiography<br>
❑ Restart sildenafil/tadalafil/vardenafil one day after catheterization</div>}}
{{familytree | | | | | |!| | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | G01 | | | | | | | | | | | | | | | | | | | | | |G01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Identify ASA physical status'''<br>
❑ 1=Healthy individual with no systemic diseases<br>
❑ 2=Mild systemic disease<br>
❑ 3=Severe systemic disease<br>
❑ 4=Severe systemic disease that poses a constant  threat to the patient’s life<br>
❑ 5=Moribund patient not expected to survive  without the operation/procedure<br>
❑ 6=Patient declared brain-dead or whose organs  are being removed for donation</div>}}
{{familytree | | | |,|-|^|-|.| | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | I01 | | I02 | | | | | | | | | | | | | | | | | | | |I01=ASA physical status ≥ 4|I02=ASA physical status < 4}}
{{familytree | | | |!| | | |!| | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | J01 | | |!| | | | | | | | | | | | | | | | | | | | |J01=Consult anesthesia}}
{{familytree | | | |`|-|v|-|'| | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | K01 | | | | | | | | | | | | | | | | | | | | | |K01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Perform pre-procedure routine work-up'''<br>
❑ Complete blood count (CBC)<br>
❑ Platelet count (Administration of unfractionated heparin, low molecular weight heparinoids, and parenteral glycoprotein 2b3a inhibitors are associated with thrombocytopenia. Thrombocytopenia is a contraindication to the administration of parenteral glycoprotein 2b3a inhibitors)<br>
❑ Electrolytes panel<br>
❑ Baseline serum creatinine and BUN. Calculate and record estimated creatinine clearance/eGFR (creatinine clearance/eGFR may significantly be different from true GFR in patients with unstable renal function) <br>
❑ Glycemia<br>
❑ Beta-HCG within 2 weeks of procedure for women of child-bearing age<br>
❑ Baseline ECG within 24 hours of procedure
:❑ Assess baseline ischemic changes
:❑ Presence of baseline bundle branch block (BBB) (Cardiac catheterization may damage HIS  system and induce BBB)<br>
❑ PT/INR within 24 hours, especially if patient is receiving warfarin (INR > 1.8 is a relative contraindication of cardiac catheterization)<br>
❑ CXR if patient suspected to have pulmonary edema or other diseases</div>}}
{{familytree | | | | | |!| | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | L01 | | | | | | | | | | | | | | | | | | | | | |L01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Address relevant and significant comorbidities'''<br><br>
❑ Prolonged INR (>1.8) 24 hours prior to procedure<br>
:❑ Administer low-dose vitamin K 1-2 mg PO
:❑ Repeat INR and confirm new INR < 1.8 (preferable INR ≤ 1.4). If INR still > 1.8
::❑ Administer additional vitamin K 2-4 mg PO if anticipated procedure is > 24 hours later. Administer more  doses of low-dose vitamin K (1-2 mg PO) if INR still high
::❑ Cancel transfemoral approach (except if emergency) if INR does not normalize in time of procedure
::❑ Consider transradial approach if radial artery accessible to reduce risk of bleeding
::❑ Consider transfusion of fresh frozen plasma (FFP)<br>
❑ Renal insufficiency (CrCl < 60 ml/min)<br>
:❑ Saline administration
::❑ In patients with no CHF, administer 0.9% or 0.45% normal saline: 1 mL/ kg/ hour (MAX 100 ml/hour) for 12 hours before contrast '''AND''' 12 hours after contrast) in patients with no CHF
::❑ In patients with CHF, administer 0.45% normal saline: 0.5 ml/kg/hr (MAX 50 ml/hr) 12 hrs before contrast '''AND''' 12 hours after contrast
:❑ Consider administration of NaHCO3
::❑ Mix 150 mEq of NaHCO3  in 1 liter of D5W in non-diabetic patients OR mix 150 mEq of NaHCO3 in 1 liter of sterile water in diabetic patients.
::❑ Administer 3 ml/kg bolus (MAX 300 ml) for 1 hour prior to procedure AND 1 mL/kg/hour (MAX 100 ml/hr) during the procedure AND 1 mg/kg/hour for 6 hours post-procedure
:❑ Follow-up serum creatinine 2 to 5 days following catheterization<br>
❑ Contrast allergy<br>
:❑ Administer the following regimen before the procedure (controversial timing)
:❑ Regimen 1
::❑ Methylprednisolone 60 mg IV once, '''AND'''
::❑ Diphenhydramine 50 mg IV once, '''AND'''
::❑ Cimetidine 300 mg (or alternative H2 blocker) IV once
:❑ Regimen 2
::❑ Prednisolone 50 mg PO at 13 hours, 7 hours, and 1 hour (total of 3 doses) before procedure</div>}}
{{familytree | | | | | |!| | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | M01 | | | | | | | | | | | | | | | | | | | | | |M01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Confirm pre-cath checklist on the day of the procedure'''
❑ Confirm patient full name<br>
❑ Identify indication for procedure<br>
❑ Planned procedure<br>
:❑ Diagnostic cardiac catheterization
:❑ Diagnostic cardiac catheterization with possible PCI
:❑ PCI
❑ Appropriate history and physical examination documented in patient record<br>
❑ Informed consent is filled within 30 days, complete, signed, and available in patient record<br>
❑ Candidacy for DES<br>
:❑ Does the patient have significant anemia (Hct < 30%)
:❑ Has the patient had any major surgery in the past month or is anticipating any major surgery in the next year?
:❑ Does the patient have clinically overt bleeding?
:❑ Is the patient receiving chronic anticoagulation (e.g. warfarin or dabigatran)
:❑ Does the patient have a history of medications non-adherence?
:❑ Does the patient have someone available to transport to and from the hospital?<br>
❑ Allergies and adverse drug reactions<br>
:❑ Contrast allergy. If yes, was the patient pre-treated?
:❑ Aspirin allergy. If yes, does the patient need desensitization?
:❑ Latex allergy: If yes, remove all latex products from procedural use
:❑ Heparin induced thrombocytopenia (HIT): If yes, consider alterative antithrombotic agent
:❑ Patient known to have multiple allergies? If yes, did you consider pretreatment?<br>
❑ Medications<br>
:❑ Was the patient administered ANY of the following medications within the last 48 hours prior to catheterization?
::❑ Aspirin
::❑ Clopidogrel
::❑ Metformin
::❑ Phosphodiesterase inhibitors (e.g. Tadalafil, sildenafil, or similar drugs)
::❑ Warfarin. If yes, what the patient’s pre-op (within 48 hours) INR?
::❑ Low molecular weight heparin (LMWH). If yes, when was last dose?
::❑ Other chronic anticoagualants (e.g. dabigatran, NOACs)
❑ ASA physical status available<br>
❑ Modified mallampati score available<br>
❑ Does patient have any contraindication to sedation?<br><span style="font-size:65%;color:red">Sedatives are contraindicated in [[drug allergy|<span style="color:red;">drug allergy</span>]], <span style="color:red;"> < 6 hours of NPO for solid food/non-clear liquids</span>, <span style="color:red;">< 2 hours of NPO for clear liquids</span>, [[abnormal ECG findings|<span style="color:red;">abnormal ECG findings</span>]], <span style="color:red;">any condition that might compromise airway patency or that would interfere with intubation</span>, [[hemodynamic instability|<span style="color:red;">hemodynamic instability</span>]], or [[clinically significant comorbidities|<span style="color:red;">clinically significant comorbidities</span>]]</span><br>
❑ Patient's height (in meter) and weight (in kilograms) recorded? <br>
❑ Pre-procedural work-up available '''AND''' reviewed (CBC, electrolytes, glycemia, PT/INR, creatinine, BUN, PT/INR within 24 hours if receiving warfarin, ECG within 24 hours, CXR if applicable)
:❑ Renal function (serum creatinine, BUN, creatinine clearance/eGFR)
:❑ Bleeding risk (anemia, thrombocytopenia, prolonged INR/PT)
:❑ Cardiac assessment (ECG)</div>}}
{{familytree | | | | | |!| | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | N01 | | | | | | | | | | | | | | | | | | | | | |N01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Administer Preprocedural Drugs'''<br><br>
'''''Antiplatelet therapy'''''<br>
''Aspirin''<br>
❑ Administer aspirin 325 mg PO once at least 2 hours before any cardiac catheterization procedure<br>
''Thienopyridine'' should be administered '''ONLY''' when there is intention for PCI or high likelihood to perform PCI during left heart catheterization. Generally, right heart catheterizations do not require administration of thienopyridine <br>
❑ Administer '''ANY''' of the following thienopyridines at least 2 to 6 hours before the procedure ONLY when there is intention for PCI or high likelihood to perform PCI: <br>
:❑ Clopidogrel 600 mg (loading dose) PO once, '''OR'''
:❑ Prasugrel 60 mg (loading dose) PO once, '''OR'''
:❑ Ticagrelor 180 mg (loading dose) PO once<br><br>
'''''Conscious Sedation'''''<br>
<span style="font-size:65%;color:red">Sedatives are contraindicated in [[drug allergy|<span style="color:red;">drug allergy</span>]], <span style="color:red;"> < 6 hours of NPO for solid food/non-clear liquids</span>, <span style="color:red;">< 2 hours of NPO for clear liquids</span>, [[abnormal ECG findings|<span style="color:red;">abnormal ECG findings</span>]], <span style="color:red;">any condition that might compromise airway patency or that would interfere with intubation</span>, [[hemodynamic instability|<span style="color:red;">hemodynamic instability</span>]], or [[clinically significant comorbidities|<span style="color:red;">clinically significant comorbidities</span>]]</span><br>
❑ Administer diazepam 5-10 mg PO once<br>
❑ Additional drugs may be administered pre-procedure, but are usually administered once patient is inside the cath lab. These drugs (combination) include:<br>
:❑ Fentanyl 25 to 50 microgram IV, '''AND'''
:❑ Midazolam 1 to 2 mg IV <br><br>
'''''Consider antihistamine'''''<br>
❑ Consider administration of diphenhydramine (Bendaryl) 25 mg PO once<br><br>
'''''Consider anti-nausea agents'''''<br>
❑ Consider administration of ondansetron (Zofran) 4 mg IV once</div>}}
{{familytree | | | | | |!| | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | O01 | | | | | | | | | | | | | | | | | | | | | |O01=Transfer patient to cath lab}}
{{familytree/end}}
==Do's==
*Perform a transradial approach instead of a transfemoral appraoach if radial artery is patent
*Hold anticoagulants, anti-diabetic agents, and phosphodiesterase inhibitors before the procedure
*Keep patient NPO at least 6 hours before the procedure
*Prepare the patient before the procedure if he is known to have contrast allergy, renal insufficiency, or diabetes mellitus
*Administer minimal among of contrast dye before a full injection to ensure the patient is not allergic or to confirm is adequately prepared
*Maintain the patient in a conscious state when administering sedatives
==Don'ts==
*Do not perform right heart catheterization (RHC) for routine management of pulmonary edema
*Do not perform RHC before a trial of intravascular volume expansion is attempted for low-risk patients
*Do not perform RHC for patients with certain cardiac tamponade, in whom RHC would delay treatment
*Do not perform RHC for patients with compensated heart failure undergoing low-risk non-cardiac surgery
*Do not administer thienopyridine if PCI will not be performed or unlikely to be performed during catheterization
*Do not remove compressive gauze at the site of injection before 24 hours of catheterization or before the patient is being discharged
*Do not insert the catheter at an infected site
*Do not perform catheterization if patient is pregnant (relative contraindication)
*Do not perform catheterization if the patient has uncontrolled hypertension or uncontrolled glycemia
==Don'ts==


==Abdominal Aortic Aneurysm==
==Abdominal Aortic Aneurysm==

Revision as of 19:45, 17 April 2015

Abdominal Aortic Aneurysm

Overview

Classification

Abdominal aortic aneurysms may be classified based on the size of the aneurysm:

  • Small aneurysm: Diameter < 4.0 cm
  • Medium aneurysm: Diameter between 4.0 and 5.5 cm
  • Large aneurysm: Diameter ≥ 5.5 cm
  • Very large aneurysm: Diameter ≥ 6.0 cm

Abdominal aortic aneurysms may also be classified based on the rate of aneurysm expansion:

  • Non-rapidly expanding aneurysm: Diameter increase of ≤ 0.5 cm within 6 months OR ≤ 1.0 cm within 12 months
  • Rapidly expanding aneurysm: Diameter increase of > 0.5 cm within 6 months OR > 1.0 cm within 12 months

Causes

Life Threatening Causes

  • Ruptured AAA
  • Infected (mycotic) aneurysm
  • Inflammatory AAA
  • Aortovenous fistula
  • Aortoenteric fistula
  • Lower extremity thromboembolism

Risk Factors for Development of AAA

  • Old age 50 > years
  • Greater height
  • Male gender
  • Caucasian race
  • Smoking
  • History of CAD and atherosclerotic cardiovascular disease
  • History of hypertension
  • Dyslipidemia
  • Family history of AAA
  • Personal history of peripheral artery aneurysms

Risk Factors for Rapid Expansion or Rupture of AAA

  • Female gender
  • Advanced age > 50 years
  • Smoking
  • Advanced atherosclerosis
  • History of prior stroke
  • Hypertension
  • Transplantation (cardiac or renal)
  • Known reduced FEV1 (obstructive pulmonary disease)

FIRE: Focused Initial Rapid Evaluation

A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate surgical intervention. Boxes in red signify that an urgent management is needed.

 
 
 
 
 
 
 
Identify cardinal findings that increase the pre-test probability of abdominal aortic aneurysm (AAA) rupture and development of complications

❑ Known large AAA > 5.5 cm
❑ Known rapid AAA expansion rate > 0.5 cm/6 months OR 1.0 cm/year
❑ Known infective endocarditis (high risk for infected aneurysm)
❑ Acute abdominal/back pain that may radiate to buttocks, groin region, or lower extremities

❑ Tearing/sharp quality
❑ Increasing in intensity

❑ Pulsating abdominal mass
❑ Hypotension or shock
❑ Oliguria or anuria
❑ Muscular weakness
❑ Lower extremity numbness and/or tingling
❑ Cold extremities
❑ Peripheral cyanosis
❑ Acute limb pain
❑ Fever or sepsis
❑ Altered mental status
❑ Unexplained syncope
❑ Coma
❑ Presence of risk factors associated with rapid expansion or rupture of AAA

❑ Female gender
❑ Advanced age > 50 years
❑ Smoking
❑ Advanced atherosclerosis
❑ History of prior stroke
❑ Hypertension
❑ Transplantation (cardiac or renal)
❑ Known reduced FEV1 (obstructive pulmonary disease)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Rule out life threatening alternative diagnoses:
Acute coronary syndromes
(suggestive findings: Chest pain, Abdominal pain, back pain, interscapular pain, Hypotension, Dyspnea, Nausea, Cold sweats
Peritonitis
(suggestive findings: Abdominal pain, Abdominal guarding, Abdominal rigidity, Fever, Hypotension
Bowel ischemia
(suggestive findings: Abdominal pain, Vomiting, Fever, Absence of abdominal tenderness
Perforated ulcer
(suggestive findings: Abdominal pain, Vomiting, Hematemesis, Fever
Intestinal obstruction
(suggestive findings: Abdominal pain, Bilious vomiting, Abdmoninal tenderness, Fever, Abdmoninal distention
Aortic dissection
(suggestive findings: back pain, interscapular pain, aortic regurgitation, pulsus paradoxus, blood pressure discrepancy between the arms)
Pulmonary embolism
(suggestive findings: acute onset of dyspnea, tachypnea, hemoptysis, previous DVT)
Cardiac tamponade
(suggestive findings: hypotension, jugular venous distention, muffled heart sounds, pulsus paradoxus)
Tension pneumothorax
(suggestive findings: sudden dyspnea, tachycardia, chest trauma, unilateral absence of breath sound)

Esophageal rupture
(suggestive findings: vomiting, subcutaneous emphysema)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stabilize and resuscitate the patient

❑ Attend to the patient's ABCs (Airway, Breathing, Circulation)

❑ Consider endotracheal intubation if the patient's airway is compromised, has a Glasgow coma scale (GCS < 8) or profound hemodynamic instability
❑ Administer oxygen and maintain a saturation >90%
❑ Secure 2 large-bore intravenous (IV) lines
❑ Administer fluids to reach a target systolic blood pressure (SBP) of 70 to 100 mm Hg. Excessive fluid administration in AAA is associated with worse outcomes
❑ Do NOT routinely administer vasopressors if patient is hypotensive at presentation. Vasopressor administration in AAA is controversial. Consider ANY of the following vasopressors only if patient remains hypotensive despite fluids
❑ Norepinephrine 0.05 microgram/kg/minute IV; titrate by 0.02 microgram/kg/minute every 5 minutes, OR
❑ Phenylephrine 100-180 microgram/minute; titrate by 25 microgram/minute every 10 minutes, OR
❑ Dopamine 5 microgram/kg/minute; titrate by 5 microgram/kg/minute every 10 minutes

❑ Obtain 12 lead ECG and place the patient on a cardiac monitor
❑ Place an indwelling urethral catheter and monitor urine output
❑ Frequently assess mental status and check for focal neurologic deficits
❑ Type and crossmatch 6 to 10 units of PRBC. FFP may also be needed in cases of massive transfusion

❑ Do not administer pre-op transfusions except if patient is unconscious or has signs or myocardial infarction

❑ Withdraw blood for CBC, electrolytes, BUN, serum creatinine, LFTS, PT, PTT, troponin I, CK, CK-MB, CRP or ESR, and multiple blood cultures
Pain management
❑ Assess pain severity (self-report NRS scale 0 to 10; unconscious BPS 3-12 or CPOT 0-8). Pain considered significant if NRS≥4, BPS<5, or CPOT≥3
❑ Administer IV opioids: Morphine 4-10 mg IV every 4 hours, infused over 4-5 minutes (dose range: 5-15 mg)
❑ Consider pre-op epidural catheter if patient meets ALL of the following criteria

❑ Patient hemodynamically stable, AND
❑ Contained leak, AND
❑ Satisfactory coagulation profile

❑ Maintain patient in a conscious state

❑ Monitor any significant undesired drop in blood pressure as pain medications are administered
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient hemodynamically unstable despite resuscitation?

❑ Hypotension (SBP < 90 mm Hg) despite resuscitation

❑ Tachycardia (HR > 100 bpm) despite resuscitation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes. Patient is still hemodynamically unstable despite resuscitation.
 
 
 
 
 
No. Patient is hemodynamically stable following resuscitation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Is the patient known to have an AAA?
 
 
 
 
 
Can patient have CT scan with contrast?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Proceed to operating room without further work-up
 
❑ Obtain focused bedside ultrasound
 
❑ Obtain CT scan with IV contrast of abdominal aorta and iliac arteries
 
❑ Obtain CT scan without IV contrast of abdominal aorta and iliac arteries
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AAA confirmed on imaging?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider alternative diagnoses
 
 
 
 
 
 
 
 
 
 
 
 

Evaluate need for further management of the following AAA complications

For patients suspected to have thromboembolism
❑ Obtain Duplex ultrasound of affected extremities
❑ Consider CT scan of aorta from aortic valves to iliac bifurcation

For patients suspected to have infected (mycotic) aneurysm
❑ Consider gallium scanning or 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) to evaluate disease activity

For patients suspected to have aortovenous fistula
❑ Obtain CT angiography

For patients suspected to have aortoenteric fistula
❑ Perform EGD to rule out other possible etiologies of GI bleed among hemodynamically stable patients
❑ Obtain CT scan with IV contrast of the abdomen and iliac arteries

❑ Consider arteriography
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Administer antimicrobial therapy

Once diagnosis of complicated AAA is confirmed, all patients require blood cultures and empirical antibiotic therapy for gram-positive and gram-negative coverage (even if afebrile at presentation)
❑ Withdraw multiple sets of blood culture (if blood cultures were not withdrawn initially)
❑ Administer empiric combination antibiotic therapy

❑ Vancomycin 1-1.5g IV every 12 hours
PLUS only one of the following:
❑ Ceftriaxone 2 g IV every 12 hours, OR
❑ Cefuroxime 1.5 g IV every 4 hours, OR
❑ Piperacillin-tazobactam
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proceed to further management
 
 
 
 
 
 
 
 
 

Diagnosis

Treatment

Shown below is an algorithm summarizing the management of abdominal aortic aneurysm.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confirmed AAA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symptoms present?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Perform imaging using ANY of the following imaging modalities for the abdominal aorta and iliac arteries:
❑ Ultrasound
❑ CT Scan
❑ MRI
 
 
 
 
 
 
 
 
 
 
 
 
Hemodynamically stable?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adequate imaging?
 
 
 
 
 
 
 
 
No
 
 
 
 
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stabilize and resuscitate the patient

❑ Attend to the patient's ABCs (Airway, Breathing, Circulation)

❑ Consider endotracheal intubation if the patient's airway is compromised, has a Glasgow coma scale (GCS < 8) or profound hemodynamic instability
❑ Administer oxygen and maintain a saturation >90%
❑ Secure 2 large-bore intravenous (IV) lines
❑ Administer fluids to reach a target systolic blood pressure (SBP) of 70 to 100 mm Hg. Excessive fluid administration in AAA is associated with worse outcomes
❑ Do NOT routinely administer vasopressors if patient is hypotensive at presentation. Vasopressor administration in AAA is controversial. Consider ANY of the following vasopressors only if patient remains hypotensive despite fluids
❑ Norepinephrine 0.05 microgram/kg/minute IV; titrate by 0.02 microgram/kg/minute every 5 minutes, OR
❑ Phenylephrine 100-180 microgram/minute; titrate by 25 microgram/minute every 10 minutes, OR
❑ Dopamine 5 microgram/kg/minute; titrate by 5 microgram/kg/minute every 10 minutes

❑ Place an indwelling urethral catheter and monitor urine output

❑ Frequently assess mental status and check for focal neurologic deficits
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Repeat imaging
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AAA meets AT LEAST ONE of the following criteria for surgical or endovascular intervention?

❑ AAA > 5.5 cm, OR
❑ Rapidly expanding AAA, OR

❑ AAA plus peripheral arterial aneurysm or peripheral artery disease
 
 
 
 
 
 
 
 
 
 
Perform pre-operative work-up

❑ Obtain 12 lead ECG and place the patient on a cardiac monitor
❑ Perform CT scan of the abdominal aorta and iliac arteries. (CT scan preferably WITH contrast, but may be WITHOUT contrast for patients at high risk of contrast-induced complications).
❑ Type and crossmatch 6 to 10 units of PRBC. FFP may also be needed in cases of massive transfusion

❑ Do not administer pre-op transfusions except if patient is unconscious or has signs or myocardial infarction
❑ Withdraw blood for CBC, electrolytes, BUN, serum creatinine, LFTS, PT, PTT, troponin I, CK, CK-MB, CRP or ESR, and multiple blood cultures
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pain management

❑ Assess pain severity (self-report NRS scale 0 to 10; unconscious BPS 3-12 or CPOT 0-8). Pain considered significant if NRS≥4, BPS<5, or CPOT≥3
❑ Administer IV opioids: Morphine 4-10 mg IV every 4 hours, infused over 4-5 minutes (dose range: 5-15 mg)
❑ Consider pre-op epidural catheter if patient meets ALL of the following criteria

❑ Patient hemodynamically stable, AND
❑ Contained leak, AND
❑ Satisfactory coagulation profile

❑ Maintain patient in a conscious state

❑ Monitor any significant undesired drop in blood pressure as pain medications are administered
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Manage modifiable risk factors of asymptomatic AAA

❑ Administer aspirin 80 to 100 mg once daily if patient has no contraindication to aspirin therapy

❑ Administer statin therapy (e.g. simvastatin 40 mg once daily) if patient has no contraindication to statin therapy

❑ Manage hypertension based on guidelines for the management of hypertension (There are currently no recommended antihypertensive pharmacologic therapies for the management of AAA)

❑ Recommend smoking cessation

❑ Recommend moderate physical activity at least 4 times per week (e.g. running, swimming, golfing)

❑ Do NOT recommend intense physical activity (e.g. heavy lifting) due to increased risk of AAA rupture

❑ Provide appropriate counseling for patients at high risk of AAA expansion and rupture
 
 
 
 
 
 
 
 
 
 
 
 
 
Administer antimicrobial therapy

Once diagnosis of complicated AAA is confirmed, all patients require blood cultures and empirical antibiotic therapy for gram-positive and gram-negative coverage (even if afebrile at presentation)
❑ Withdraw multiple sets of blood culture (if blood cultures were not withdrawn initially)
❑ Administer empiric combination antibiotic therapy

❑ Vancomycin 1-1.5g IV every 12 hours
PLUS only one of the following:
❑ Ceftriaxone 2 g IV every 12 hours, OR
❑ Cefuroxime 1.5 g IV every 4 hours, OR
❑ Piperacillin-tazobactam
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Follow-Up

❑ Schedule routine follow-up visits with abdominal ultrasound imaging at regular time intervals to monitor patients who are candidates for surgical or endovascular repair.
❑ Do NOT schedule follow-up visits for patients who refuse either surgical or endovascular repair or who are not adequate candidates for either surgical or endovascular repair.

Optimal interval between visits has not yet been established and is controversial. Aneurysm size should determine the frequency of follow-up ultrasound, and the following intervals may be considered based on various guidelines.
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluate need for further management of the following AAA complications

For patients suspected to have thromboembolism
❑ Obtain Duplex ultrasound of affected extremities
❑ Consider CT scan of aorta from aortic valves to iliac bifurcation

For patients suspected to have infected (mycotic) aneurysm
❑ Consider gallium scanning or 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) to evaluate disease activity

For patients suspected to have aortovenous fistula
❑ Obtain CT angiography

For patients suspected to have aortoenteric fistula
❑ Perform EGD to rule out other possible etiologies of GI bleed among hemodynamically stable patients
❑ Obtain CT scan with IV contrast of the abdomen and iliac arteries
❑ Consider arteriography

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aneurysm size between 5 and 5.5 cm
❑ Consider routine ultrasound every 3 months
 
Aneurysm size between 4.5 and 4.9 cm
❑ Consider routine ultrasound every 12 months (1 year)
 
Aneurysm size between 4.0 and 4.4 cm
❑ Consider routine ultrasound every 24 months (2 years)
 
Aneurysm size between 3.5 to 3.8 cm
❑ Consider routine ultrasound every 36 months (3 years)
 
Aneurysm size between 2.6 to 2.9 cm
❑ Consider routine ultrasound every 60 months (5 years)
 
Evaluate patient's surgical risk
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High surgical risk
 
 
 
 
 
Low to moderate surgical risk
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient performed CT scan of the abdominal aorta and iliac arteries WITH contrast?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CT scan demonstrated adequate aortic anatomy and integrity suitable for endovascular procedure?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider any of the following:

❑ Endovascular repair, OR

❑ Open AAA repair
 
 
 
 
 
 
 
Open AAA Repair
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Screening

Screening for AAA is currently recommended only once in the following patient groups:

  • Men between the age of 65 and 75 years and who have ever smoked
  • Men aged 60 years or older with a sibling or a parent with abdominal aortic aneurysm

There are currently no recommendations to screen AAA in women, but women are at increased risk of AAA expansion or rupture. Some experts recommend one-time screening in women with risk factors of developing AAA (such as smoking or positive family history)

Do's

Don'ts